Oncogenic mutations of molecules involved in the mitogen-activated protein kinase (MAPK) pathways provide signals mediating both tumor growth and invasion in various cancers including melanomas. BRAF somatic mutations, found in 66% of melanomas, have NIH3T3 transforming ability with the elevated kinase activity in vitro. We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild type or the most frequently mutated form of BRAF (V599E) in 10 melanoma cell lines, and found that RNAi inhibited the growth of most melanoma cell lines in vitro as well as in vivo, which was accompanied by decrease of both BRAF protein and ERK phosphorylation. Interestingly, the mutated BRAF (V599E)-specific siRNA inhibited the growth and MAPK activity of only melanoma cell lines with this mutation. Furthermore, BRAF RNAi inhibited matrigel invasion of melanoma cells accompanied with a decrease of matrix metalloproteinase activity and b 1 integrin expression. These results clarify that the mutated BRAF (V599E) is essentially involved in malignant phenotype of melanoma cells through the MAPK activation and is an attractive molecular target for melanoma treatment. The lentivirus-mediated RNAi specific for oncogenic mutations may be a powerful technique for gene therapy of cancer.
Introduction
RNA interference (RNAi) is an evolutionarily conserved process whereby double-stranded RNA (dsRNA) induces a sequence-specific degradation of homologous mRNA, leading to post-transcriptional gene silencing (Hannon, 2002) . This involves cleavage of dsRNA into short (21-23 nt) small interfering RNAs (siRNAs) with characteristic 2 nt 3 0 -overhanging ends, which is mediated by Dicer (Bernstein et al., 2001) . However, in mammalian cells, dsRNA larger than 30 base pairs can trigger an interferon response that globally represses gene expression. This nonspecific gene silencing effect could be avoided by introducing synthetic siRNAs of 21 nt lengths (Elbashir et al., 2001) or siRNA expression vectors (Tuschl, 2002) into mammalian cells.
The Ras/Raf/MEK/ERK pathway is one of the major signal transduction pathway involved in cellular growth (Cobb, 1999) . Many melanomas are known to have activating mutations of either N-Ras or BRAF, suggesting that the downstream effector ERK may play a major role in the malignant phenotype of melanoma (Smalley, 2003) . BRAF missense mutations were found in 66% of melanomas and all of the mutations located within the kinase domain, particularly with a single substitution (T-A) of glutamic acid for valine (V599E) in 80% of theses mutations (Davies et al., 2002) . These mutations were associated with a 10-12-fold increase of the kinase activity and a 70-138-fold increase of transformation ability in NIH3T3 cells (Davies et al., 2002) . These results indicated that these BRAF mutations were involved in oncogenic transformation of melanoma and may be good targets for treatment.
However, the effects of the mutated BRAF observed in the transient transfection into COS or NIH3T3 cells might have overestimated the activity of mutated BRAF because of much higher expression than actual in vivo expression. Thus, it is important to evaluate the role of the mutated BRAF on the activation of mitogenactivated protein kinase (MAPK) pathway and cellular growth at a more pathophysiological level particularly when considering BRAF as a therapeutic target, which has not been extensively investigated. Therefore, we have attempted to evaluate effects of the mutated and wild-type BRAF on proliferation and invasive ability of melanoma cells by suppressing the BRAF expression with RNAi using lentiviral vectors in mutation-specific and nonspecific ways. Since the gene silencing effect by RNAi is highly sequence-specific, allowing discrimination of only a single base substitution (Brummelkamp et al., 2002a, b; Kawasaki and Taira, 2003) , BRAF V599E missense mutation-specific RNAi was attempted.
Although several siRNA expression systems using plasmid vectors (Lee et al., 2002; Miyagishi and Taira, 2002; Paddison et al., 2002; Paul et al., 2002; Sui et al., 2002; Yu et al., 2002; Kawasaki and Taira, 2003) or viral vectors (Abbas-Terki et al., 2002; Barton and Medzhitov, 2002; Brummelkamp et al., 2002b; Devroe and Silver, 2002; Xia et al., 2002; Qin et al., 2003; Rubinson et al., 2003; Tiscornia et al., 2003) containing RNA Pol III promoters have been reported, we used a lentiviral vector for siRNA expression because of its high transduction ability on various types of cells and stable gene transduction for long-term RNAi effects. We found that in vitro and in vivo growth and in vitro invasive ability of melanoma cells were inhibited by infecting lentivirus vectors expressing siRNAs for BRAF, indicating that BRAF is an excellent molecular target for the treatment of melanoma, including gene therapy.
Results

siRNA-expressing HIV vectors for BRAF
Three siRNA target sites, #1' including the V599E mutation, and #10 and #7 0 without the mutation, were selected within the coding region of the BRAF mRNA. We constructed three siRNA-expressing HIV vectors specific for these three target sites. The HIV vector contains an siRNA expression unit (human U6 promoter and two BspMI cloning sites) between central termination sequence (CTS) and a green fluorescence protein (GFP) expression unit ( Figure 1a ) (Miyagishi et al., in press ). The synthetic oligonucleotides (the target sense -linker -the target antisense -stop sequence (TTTTT)) were subcloned into the two BspMI sites. The siRNAs were produced by human U6 promoters as a fold-back stem-loop structure. Transduction efficiency was monitored by evaluating GFP expression.
RNAi effects of these BRAF siRNA HIV vectors were evaluated by infecting 293T cells (V599E mutation negative) and A375mel cells (V599E mutation positive) (Figure 1b) . Decrease of the BRAF protein was observed in both the 293T embryonic kidney cell line and the A375mel melanoma cell line with both siRNA #10 and #7 0 , and was observed only in A375mel with siRNA #1 0 , indicating that the V599E mutation-directed siRNA #1 0 is highly selective for the mutation.
Inhibition of MAP kinase activity and in vitro proliferation of melanoma cell lines by BRAF RNAi
To evaluate the effects of BRAF RNAi on various melanoma cell lines with or without the V599E mutation (Table 1) , 10 melanoma cell lines including eight cell lines with the BRAF V599E mutation were infected with control GL3B (anti-firefly luciferase siRNA) or the BRAF siRNA (#10, #1 0 or #7 0 )-expressing HIV vectors at 50 or 100 multiplicity of infection (MOI), then in vitro cell growth was evaluated by counting cell number every 3 days until day 6 or 9. No difference of transduction efficiency was observed among the melanoma cells infected with these siRNA vectors, since equivalent GFP expression (95-100%) was detected on the last culture day by flow cytometry.
siRNA #10 (and also #7 0 in SKmel23), but not siRNA #1 0 , inhibited in vitro growth of SKmel23 and 1362mel melanoma cells, which did not have the V599E mutation ( Figure 2a) . The inhibition by two siRNAs targeting to different sequences of BRAF indicated that it is specifically caused by downregulation of BRAF. Western blot analysis (Figure 2b ) demonstrated that siRNA #10 (and also #7 0 in SKmel23), decreased the BRAF protein, while siRNA #1 0 did not. siRNA #1 0 , however, inhibited growth of other eight melanoma cell lines with the V599E mutation to the same degree as siRNA #10 0 are specific for wild-type BRAF mRNA, while siRNA #1 0 is specific for mutated BRAF (V599E) mRNA. Western blot analysis of BRAF showed that siRNA #1 0 decreased BRAF protein only in A375mel melanoma cell line with the mutated BRAF (V599E), but not in 293T cells without it, while siRNAs #10 and #7 0 decreased the BRAF protein in both A375mel cells and 293T cells Figure 2c ). siRNA #7 0 was less inhibitory than siRNA #10 in seven melanoma cell lines (Figure 2a and c) . Western blot analysis of the BRAF protein in the eight melanoma cell lines with the V599E mutation ( Figure 2d ) demonstrated that all siRNAs decreased the BRAF protein and suppressed phosphorylation of a downstream MAPK, ERK. On the other hand, normal primary fibroblasts were not affected by siRNA #1 0 in terms of cellar growth and ERK phosphorylation levels ( Figure 2e) .
Interestingly, the in vitro cell growth correlated with the phosphorylation of ERK, but not with the BRAF protein level, when melanoma cells with V599E mutation were infected with siRNA #1 0 (Figure 2c  and d) . The suppression of the ERK phosphorylation and cell growth inhibition by siRNA #1 0 was equivalent to or even stronger than the siRNAs #10 and #7 0 , although the BRAF protein was less decreased by siRNA #1 0 than by siRNA #10 or #7 0 as observed in A375mel, 397mel, 526mel, 624mel, 1363mel and 888mel. This may be explained by 10-12-fold higher kinase activity of the mutated BRAF than wild-type BRAF as previously reported (Davies et al., 2002) . To clarify the significance of the mutated BRAF on the MAPK signal pathway, we also evaluated wild-type-directed siRNA #1 0 (wt) designed with the same region sequences as the mutation-directed siRNA #1 0 (mt), and found a superior suppression with siRNA #1 0 (mt) in the representative 526 mel melanoma cell line (Figure 2f ). Most melanoma cell lines infected with the BRAF siRNA vectors eventually grow for 6 or 9 days after infection with the BRAF siRNA, although to a lesser degree than with the control vector (Figure 2a and c).
Clear cell death was observed in only 888mel among the 10 melanoma cell lines after infection with BRAF siRNA #10, #1 0 and #7 0 , but not with control GL3B (Figure 2c ). Apoptosis was not observed in 888mel, when dying 888mel was evaluated using DNA fragmentation assay by the agarose gel electrophoresis, and flow cytometric analysis with annexin V-FITC and propidium iodide (PI) (data not shown). 624Amel was the most resistant to the BRAF siRNAs among the 10 melanoma cell lines (Figure 2c ). Although BRAF siRNA #10 and #7 0 decreased the BRAF protein, ERK phosphorylation was not observed even with infection of the control GL3B, indicating a less important role of the BRAF-ERK pathway in the proliferation of 624Amel (Figure 2d ).
BRAF RNAi leads to upregulation of ARAF and downregulation of MEK1
We next examined in more detail effects of BRAF RNAi on MAPK signaling pathways. Stimulation of the siRNA #10-infected 928mel with phorbol 12-myristate 13-acetate (PMA), which directly activates c-raf-1, only slightly increased ERK phosphorylation, which was less than we expected, possibly through activation of MEK ( Figure 2a ). To rule out inhibitory effect of BRAF RNAi on the downstream MAPK signaling, we evaluated other MAPK signaling molecules, including ARAF, c-raf-1, MEK1, MEK2, ERK1 and ERK2. Interestingly, upregulation of ARAF and downregulation of MEK1 were observed (Figure 3a) . The same changes were also observed in A375mel transduced with BRAF siRNA #10, #1 0 and #7 0 (Figure 3b ). Northern blot analysis did not show any difference in mRNA expression of ARAF and MEK1 among A375mel cells transduced with control GL3B, BRAF siRNA #10, #1 0 or #7 0 (Figure 3c ), suggesting post-translational alternations. Although the mechanisms and effects of these ARAF and MEK1 changes should be investigated with further study, the BRAF-ERK pathway appears to function dominantly in melanoma cell proliferation, particularly with the BRAF mutation.
BRAF RNAi inhibited matrigel invasion of melanoma cells
Since MAP kinase pathways are also involved in tumor invasion, we have evaluated BRAF RNAi effects on the invasive ability of melanoma cell lines. A375mel and 928mel melanoma cell lines stably transduced with the control HIV lentivirus (GL3B) or three lentiviruses containing siRNAs against BRAF mRNA (siRNA #10, #1 0 or #7 0 ) were evaluated for in vitro invasive activity using a matrigel invasion assay. The number of cells passed across the matrigel layer was significantly reduced in A375mel and 928mel transduced with siRNA #10, #1 0 or #7 0 , compared to siRNA GL3B (Figure 4a ). The inhibition by three siRNAs targeting to the different BRAF sequences indicated that it was specifically mediated by the BRAF downregulation. The invasive activity may be inhibited through a decrease of matrix metalloproteinase (MMP)-2 activity and b 1 integrin that was observed when the invasion of A375mel cells was suppressed by infection with siRNA #10 (Figure 4b ).
BRAF RNAi inhibited in vivo tumorigenicity of melanoma
We have then evaluated effects of the BRAF RNAi on in vivo melanoma growth, since melanoma cells whose proliferation was suppressed in vitro may still grow in in vivo microenvironment by other growth signals. A375mel cells were implanted subcutaneously in NOD/SCID mice, 2 days after ex vivo transduction with the BRAF siRNA HIV vectors or the control GL3B vector. At 24 days after the implantation, A375mel cells transduced with BRAF siRNA #10 or #1 0 showed significantly reduced tumor growth compared to those with control GL3B (Figure 5 ) (Po0.05), suggesting that melanoma cells are highly dependent on the BRAF-ERK MAPK signaling pathway in in vivo growth. Considering these results of the in vitro and in vivo inhibition of proliferation and invasive ability, it is clear that the mutated BRAF is an excellent target for the treatment of melanoma.
Discussion
We have developed siRNA-expressing HIV vectors for BRAF RNAi directed for either wild-type BRAF or the mutated BRAF (V599E) mRNA, which were detected in 66% of melanoma. Although both mutation-directed or nonspecific BRAF siRNA with lentiviral vectors led to a decrease of BRAF and ERK phosphorylation, and an inhibition of melanoma growth in most melanoma cell lines evaluated, reduction of ERK phosphorylation, but not BRAF, correlated well with cell growth inhibition, indicating that mutated BRAF, which has 10-12-fold more kinase activity than wild-type BRAF, is important for melanoma cell growth. This mutation-directed RNAi did not affect the normal fibroblast culture. Since the same inhibition was observed in in vivo melanoma growth, this study demonstrates that BRAF, particularly the V599E mutation, is an attractive molecular target for the treatment of melanoma.
Among the eight melanoma cell lines with the BRAF V599E mutation, different reactions following BRAF RNAi were observed. Marked cell death by necrosis, but not by apoptosis, was seen in only 888mel. It may be because of unknown signaling difference in 888mel. Since copy numbers obtained by lentiviral vector transduction are relatively limited, use of higher expression system may result in different cellular outcomes such as induction of more cell death and apoptosis. Recently, Hingorani et al. (2003) reported that inhibition of BRAF (V599E) by using a plasmid vector expressing siRNA in one melanoma cell line, WM793, resulted in growth arrest and apoptosis in vitro, which was detected by TUNEL assay of a stable siRNA transfectant. Their results differ from ours in that induction of cell death was not in general and apoptosis was not found by inhibition of the BRAF-MAPK pathway. Since their report was based on only one cell line, more extensive investigation is necessary for the confirmation of apoptosis induction with high-copy RNAi systems.
624Amel with the V599E mutation is resistant to both the mutation-directed and nonspecific BRAF RNAi. Although ERK phosphorylation was detectable in most melanoma cell lines in usual culture condition, it was not detected in 624Amel. Activation of the BRAF-ERK pathway appears not to be important for 624Amel. The fact that the parent melanoma cell line, 624mel, was relatively sensitive for BRAF RNAi may suggest heterogeneity of tumor cell clones or the genetic changes relating to the suppression of the BRAF-MAPK pathway during cell proliferation. It should be noted that BRAF may not be critical for cell proliferation of even melanoma cells with the V599E mutation. 624mel has a mutation in phosphorylation sites (S45Y) in bcatenin, resulting in increased expression of b-catenin protein through poor degradation in proteosomes (Rubinfeld et al., 1997) . Thus, activation of the Wnt signal pathway is one candidate for complement proliferation of melanoma in 624mel. However, proliferation of 888mel having a mutation of another phosphorylation site of b-catenin (S37F) (Robbins et al., 1996) was strongly inhibited accompanied by cell death. Thus, the mechanism of the resistance of 624mel to BRAF RNAi remains to be further investigated and it will provide important insights for resistance of melanoma in the future anti-BRAF treatment.
MMPs are a family of proteases that are involved in matrix remodeling. Particularly, MMP-2 is involved in tumor cell invasion by degradation of basement membrane collagen (Puyraimond et al., 1999) . The MMP-2 expression was reported to be a poor prognostic factor for patients with melanoma (Vaisanen et al., Ghiso et al., 1999; Genersch et al., 2000; Santibanez et al, 2000) . Integrins are involved in metastasis of melanoma through their interaction with the extracellular matrix (ECM) components (Hynes, 1992) . The expression of a 3 b 1 integrins is important for adhesion of melanoma cells to dermal collagen as well as for prevention of apoptosis and is reported to be a prognostic factor for melanoma patients (Natali et al., 1993; Melchiori et al., 1995) . Integrins also trigger cell signalings participating in cell cycle progression and survival (Montgomery et al., 1994; Petitclerc et al., 1999) . The MAPK cascade is also involved in the expression of b integrins (Woods et al., 2001 ). Therefore, the decrease of matrigel invasion accompanied by a decrease of MMP activity and b 1 integrins possibly through the suppression of the MAP kinase activity by BRAF RNAi, demonstrated in this study (Figures 2d, 3a and b) , indicates important roles of BRAF in invasion and metastasis of melanoma, indicating that BRAF is an attractive target for inhibition of melanoma spread. When we evaluated ERK phosphorylation after overnight serum starvation, it was detected in only three melanoma cell lines, A375mel, 397mel and 526mel, of total eight melanoma cell lines tested (data not shown). The constitutive activation of the MAPK pathway by the mutated BRAF may not be so high as suggested by a previous report (Satyamoorthy et al., 2003) . No correlation was observed between detectable constitutive activation of ERK and the inhibitory effects on melanoma growth by BRAF RNAi. In this study, we unexpectedly observed an increase of ARAF and a decrease of MEK1 protein after BRAF RNAi. These changes appear to be post-translationally regulated, since no different mRNA expression was seen by Northern blot analysis. Changes of stability or degradation of these proteins may be regulated by the BRAF-MAPK pathway.
In summary, this study for the first time clarified the important roles of the mutated BRAF in melanoma proliferation in vivo as well as invasion and metastasis. Therefore, molecular target therapy using BRAF kinase inhibitors or gene therapy directed for mutated BRAF should be vigorously investigated for future clinical use. Since an efficient in vivo gene transduction will be required for RNAi to activated oncogenes in cancer gene therapy, we are now trying to establish a more highly transducible vector system by using adenoviral vectors.
Methods
Cell lines
Melanoma cell lines, 397mel, 526mel, 624mel, 624Amel, 888mel, 928mel, 1362mel and 1363mel, were generated in the Surgery Branch, National cancer Institute, National Institutes of Health, Bethesda, MD, USA, and generously provided by Dr Steven A Rosenberg (Kawakami et al., 1994) . A375mel was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Skmel23 was kindly provided by Dr T Boon, Ludiwig Institute for Cancer Research and Cellular Genetics Unit, Brussels, Belgium). These cell lines were cultured in RPMI 1640 medium supplemented with 10% FCS. Human primary fibroblasts obtained from a healthy volunteer were cultured in DMEM supplemented with 10% FCS.
HIV-U6i-GFP plasmid
The siRNA expression unit containing human U6 promoter and two BspMI sites was subcloned between CTS and GFP expression unit in an HIV vector plasmid, which is a selfinactivating (SIN) vector lacking its own promoter sequence in the 3 0 -LTR, enabling GFP expression under the control of internal CMV promoter, carrying central polypurine tract (cPPT) and woodchuck hepatitis virus post-transcriptional regulatory element (PRE) for enhanced nuclear transport of the transcribed mRNA. A series of siRNA expression plasmids were constructed based on the HIV-U6i-GFP plasmid (Figure 1a) .
HIV vectors
Three siRNA target sequences were selected for BRAF RNAi:
(1) siRNA #10 GTATCACCATCTCCATATCAT; (2) (mt) 0 -protruding ends complementary to the two BspMI sites in the HIV-U6i-GFP plasmid were then subcloned into HIV-U6i-GFP. Control GL3B siRNA (anti-firefly luciferase siRNA) HIV vector was also constructed with the target sequence GTGCGCTGCTGGTGCCAAC. These HIV vectors would produce short hairpin RNA with the linker sequence (TTCAAGAGA) forming a loop structure, then the linker would be processed by Dicer, forming a dsRNA, which acts as an siRNA. The third-generation HIV vectors were produced by transfecting 293T cells with HIV plasmid vectors, pMD.G (VSV-G env expression plasmid), pMDLg/ p.RRE (the third-generation packaging plasmid) and pRSV Rev (Rev expression plasmid) (the latter two plasmids were provided by Cell Genesys, USA), by calcium phosphate transfection. The culture supernatant was collected and used as the virus stock after concentration. The viral titer was measured by infecting 293T cells and evaluating GFP expression. 
In vitro growth inhibition assay of melanoma cells by BRAF RNAi
A total of 10 melanoma cell lines were first analysed for the presence of the BRAF V599E mutation by direct sequencing of the RT-PCR product from the melanoma RNAs. The PCR conditions were as follows: forward primer GGCTCCAGC TTGTATCACCATCTCC, reverse primer CAGGTATCC TCGTCCCAC CATAAAA, hot started at 941C for 5 min, followed by 30 cycles of denaturing at 941C for 1 min, annealing at 551C for 1 min and extension at 721C for 1 min, followed by final extension at 721C for 7 min. A total of 10 melanoma cell lines, including eight cell lines with BRAF V599E (1363mel, A375mel, 397mel, 501Amel, 526mel, 624mel, 928mel and 888mel) and two cell lines without BRAF V599E (Skmel23 and 1362mel), were infected with the BRAF siRNAexpressing HIV vectors at 50 or 100 MOI at day 0. Cell numbers were counted every 3 days by Trypan blue dye exclusion method until day 6 or 9. The siRNA HIV vector for firefly luciferase (GL3B) was used as a control. Human primary fibroblasts were infected and evaluated as melanomas as a control.
Western blot analysis for proteins involved in MAPK pathway and b 1 integrin after BRAF RNAi in melanomas Cell lysates were prepared in the lysis buffer (20 mM Tris-HCl (pH 7.5), 12.5 mM b-glycerophosphate, 2 mM EGTA, 10 mM NaF, 1 mM benzamide, 1% NP-40, protease inhibition cocktail (complete, EDTA-free (Roche, Germany)) and 1 mM Na 3 VO 4 ) from the infected melanoma cells used in in vitro growth inhibition assay after confirmation of equivalent GFP expression among the control and BRAF RNAi-infected cells by flow cytometry. The protein concentration was determined by the DC protein assay kit (Bio-Rad, USA). Anti-BRAF (Santa Cruz, USA), anti-actin (Sigma, USA), anti-ERK1 (Santa Cruz, USA), anti-ERK2 (Santa Cruz, USA), or anti-ppERK1/ 2 (Cell Signaling, USA), anti-ARAF (Becton-Dickinson, USA), anti-c-raf-1 (Becton-Dickinson, USA), anti-MEK1 (Becton-Dickinson, USA), anti-MEK2 (Santa Cruz, USA) and b1 integrin (BD Transduction, USA) Abs were used as the first antibodies. HRP-conjugated anti-IgG antibodies were used as the second antibodies and the reaction was detected by chemiluminescence with SuperSignal West Femto Maximum Sensitivity Substrate (Pierce, USA). 928mel cells transduced with HIV vectors expressing GL3B or BRAF siRNA #10 were treated with PMA (Sigma, USA) at a final concentration of 100 nM. The cell lysates were prepared 15 min after the treatment for Western blot analysis.
Northern blot anaylsis
Total RNAs were prepared from A375mel cells transduced with HIV vectors expressing GL3B and BRAF siRNA #10, #1 0 or #7 0 by using TRIzol (Invitrogen, USA). A 10 mg measure of each total RNA was fractionated by formaldehyde-containing agarose gel electrophoresis, and then transferred to a nylon membrane (Hybond-XL; Amersham Pharmacia, USA).
Radioisotope-labeled ARAF, MEK-1 or GAPDH cDNA fragments were generated using the High Prime DNA Labeling Kit (Boehringer Mannheim, Germany). Prehybridization and hybridization with the radioisotope-labeled cDNA fragments were performed using Quick Hyb solution (Stratagene, USA). Radioactive signals were detected using BAS-5000 (Fuji Film, Japan).
Animal experiments
Female NOD/SCID mice (6-week-old) (Japan CLEA, Japan) were subcutaneously implanted with half a million of A375mel melanoma cell line transduced with HIV vectors expressing GL3B, BRAF siRNA #10 or #1 0 (n ¼ 5). The tumor volume (largest diameter Â perpendicular diameter Â height) was measured every 2-3 days until day 24. The animal experimental protocol was approved by the Laboratory Animal Care and Use Committee at Keio University School of Medicine. Mice were treated according to the Guidelines for the Care and Use of Laboratory Animals of Keio University School of Medicine.
Matrigel invasion assay A375mel or 928mel melanoma cells transduced with siRNA GL3B, #10, #1 0 or #7 0 were plated in BioCoat Matrigel invasion chambers (Becton-Dickinson, MA, USA) at a cell density of 2.5 Â 10 4 cells/chamber and incubated at 371C and 5% CO 2 for 24 h. After the incubation, noninvading cells remaining on the upper surface of the chamber were removed by scrubbing with a cotton-tipped swab and the invaded cells adhering to the bottom surface of the chamber membrane were fixed and counted after cell staining with Diff-Quik stain (Sysmex, Kobe, Japan) according to the manufacturer's instructions.
Gelatin zymography
A 30mg measure of cell lysates from A375mel/GL3B or A375mel/BRAF siRNA #10 was electrophoresed in an SDS-PAGE gel containing 0.2% gelatin. The gel was rinsed in 2.5% Triton X-100 for 15 min twice, followed by incubation in TNC buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl and 10 mM CaCl 2 ) at 371C for 24 h. The gel was stained in Coomassie brilliant blue (CBB) for 30 min and the unstained band was visualized.
Statistical analysis
All statistical analyses were performed according to unpaired Student t-test.
